Literature DB >> 24815120

A nationwide population-based study of the risk of tuberculosis in different solid organ transplantations in Taiwan.

C-H Chen1, K-H Shu2, H-C Ho3, S-B Cheng4, C-C Lin5, H-J Wei4, C-H Lin6, S-N Chang6, M-J Wu7.   

Abstract

Advances in immunosuppressants for solid organ transplantation (SOT) have improved prevention and treatment of acute rejection as well as reduced the risk of chronic graft damage. However, SOT recipients are prone to developing opportunistic infections because of their long-term immunosuppressed status. Tuberculosis (TB) is a serious opportunistic infection that is associated with increased morbidity and mortality in SOT recipients. However, nationwide population-based research specifically focused on the associations between kidney transplantation (KTx), liver transplantation (LTx), and heart transplantation (HTx), and subsequent TB infection is lacking. This study was conducted using Taiwan's National Health Insurance Research Database, which provided claims data for SOT recipients from 2000 to 2009. Clinical features, treatment, and outcomes were analyzed to determine the risk for TB after SOT. In total, 153 (3.2%) RTx, 19 (1.1%) LTx, and 26 (2.8%) HTx recipients became infected with TB. Compared with non-TB patients, HTx recipients with TB had significantly higher prevalence of older age (P = .037), hypertension (P < .001), and coronary artery disease (CAD) (P = .002). There were also greater percentages of male sex (P = .018), diabetes (P = .029), hyperlipidemia (P = .016), CAD (P < .001), and chronic obstructive pulmonary disease (COPD) (P < .001) in RTx recipients with TB than in those without. In conclusion, posttransplantation TB is a serious problem worldwide, and a high index of suspicion is warranted to ensure early diagnosis and prompt initiation of treatment for TB among SOT patients. In this preliminary study, KTx recipients had a higher risk of TB infection than LTx and HTx recipients, and the high-risk factors were male sex, diabetes, hyperlipidemia, CAD, and COPD. The use of optimal immunosuppressive agents to minimize acute rejection, monitoring of high-risk recipients, prompt diagnosis, and appropriate treatment are required for the management of TB infection in endemic areas such as Taiwan.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24815120     DOI: 10.1016/j.transproceed.2013.10.051

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Indian Society of Gastroenterology consensus statements on Crohn's disease in India.

Authors:  Balakrishnan S Ramakrishna; Govind K Makharia; Vineet Ahuja; Uday C Ghoshal; Venkataraman Jayanthi; Benjamin Perakath; Philip Abraham; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra Desai; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Mathew Philip; Anna Pulimood; Amarender S Puri; Gautam Ray; Shivaram P Singh; Ajit Sood; Venkatraman Subramanian
Journal:  Indian J Gastroenterol       Date:  2015-03-14

2.  Factors influencing development and mortality of acute respiratory failure in hospitalized patient with active pulmonary tuberculosis: a 10-year retrospective review.

Authors:  Rungsun Bhurayanontachai; Kunlatida Maneenil
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Management and diagnosis of tuberculosis in solid organ transplant candidates and recipients: Expert survey and updated review.

Authors:  Kelly M Pennington; Cassie C Kennedy; Subhash Chandra; Michael Lauzardo; Maximo O Brito; David E Griffith; Barbara J Seaworth; Patricio Escalante
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2018-04-10

4.  Clinical Outcomes of Tuberculosis in Recipients After Living Donor Liver Transplantation.

Authors:  Noruel Gerard A Salvador; Sin-Yong Wee; Chih-Che Lin; Chao-Chien Wu; Hung-I Lu; Ting-Lung Lin; Wei-Feng Lee; Yi-Chia Chan; Li-Man Lin; Chao-Long Chen
Journal:  Ann Transplant       Date:  2018-10-19       Impact factor: 1.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.